<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Loratadine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Loratadine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Loratadine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11781" href="/d/html/11781.html" rel="external">see "Loratadine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12563" href="/d/html/12563.html" rel="external">see "Loratadine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F190023"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alavert [OTC];</li>
<li>Allergy Relief (Loratadine) [OTC];</li>
<li>Allergy Relief Loratadine [OTC] [DSC];</li>
<li>Allergy Relief [OTC];</li>
<li>Childrens Loratadine [OTC];</li>
<li>Claritin Allergy Childrens [OTC];</li>
<li>Claritin Childrens [OTC];</li>
<li>Claritin Reditabs [OTC];</li>
<li>Claritin [OTC];</li>
<li>FT All Day Allergy Relief [OTC];</li>
<li>FT Allergy Childrens [OTC];</li>
<li>FT Allergy Relief Childrens [OTC];</li>
<li>GoodSense Allergy Relief [OTC];</li>
<li>Loradamed [OTC];</li>
<li>Loratadine Childrens [OTC];</li>
<li>Triaminic Allerchews [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F190068"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Histamine H<sub>1</sub> Antagonist;</li>
<li>
                        Histamine H<sub>1</sub> Antagonist, Second Generation;</li>
<li>
                        Piperidine Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F190027"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7304aaf-2fc4-4567-aab9-fef6fca1cc0b">Allergic rhinitis or conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis or conjunctivitis: Oral:</b> 10 mg once daily or 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>OTC labeling </i></b>
<i>(patient-guided therapy for symptoms of hay fever or other upper respiratory allergies): </i>
<b>Oral:</b> 10 mg once daily or 5 mg twice daily; maximum dose: 10 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New onset: Oral:</b> Initial: 10 mg once daily. If symptom control is inadequate, may immediately increase to 10 mg twice daily (Asero 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic spontaneous: Oral:</b> Initial: 10 mg once daily. If symptom control is inadequate after 1 to 4 weeks, may increase to 10 mg twice daily. Although current guidelines state that antihistamine doses may be increased up to 4 times the standard dose (eg, to 20 mg twice daily), there is limited evidence for greater efficacy with this dose of loratadine, and other antihistamines are preferred. Periodically reevaluate necessity for continued treatment (EAACI [Zuberbier 2018]; Khan 2021).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990819"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Renally adjusted dose recommendations are based on a usual dose of 10 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (Matzke 1990; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: 10 mg every 48 hours (Matzke 1990; expert opinion; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (Matzke 1990): <b>Oral:</b> 10 mg every 48 hours (Matzke 1990; expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzable (large V<sub>d</sub>, highly protein bound): <b>Oral:</b> 10 mg every 48 hours (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg every 48 hours (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg every 48 hours (expert opinion).</p></div>
<div class="block doha drugH1Div" id="F50988028"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">No dosage adjustment provided in manufacturer’s labeling; however, hepatic impairment increases systemic exposure to loratadine.</p></div>
<div class="block doe drugH1Div" id="F190028"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F190047"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12563" href="/d/html/12563.html" rel="external">see "Loratadine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d0055c1-25bc-4dfa-b958-a9da36b3e3ad">Allergic symptoms, hay fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic symptoms, hay fever:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 to &lt;6 years: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: 5 mg twice daily or 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Product-specific dosing: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 to &lt;6 years: Oral: Oral liquid or chewable tablet: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Oral liquid, capsule, tablet, or chewable tablet: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Dispersible tablet: 5 mg twice daily or 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e59a61ec-4a7a-40f9-83a5-0a8d439e15d5">Urticaria, chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous (idiopathic):</b> Limited data available (Kliegman 2020; Pozzo-Magaña 2017): <b>Note:</b> Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of loratadine (as age and weight permits) as second-line treatment rather than changing therapy (Zuberbier 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to &lt;6 years: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: 10 mg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51128483"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in manufacturer's labeling, however, the following recommendations have been recommended (Aronoff 2007):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: No dosage adjustment necessary for any degree of renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51128484"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F189995"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and pediatric patients unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (adolescents and adults: 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (&lt;2%), flushing (&lt;2%), hypertension (&lt;2%), hypotension (&lt;2%), palpitations (&lt;2%), supraventricular tachycardia (&lt;2%), syncope (&lt;2%), tachycardia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (&lt;2%), diaphoresis (&lt;2%), dry hair (&lt;2%), pruritus (&lt;2%), skin photosensitivity (&lt;2%), skin rash (children: 2% to 3%), xeroderma (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (&lt;2%), heavy menstrual bleeding (&lt;2%), increased thirst (&lt;2%), weight gain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children: 2%), altered salivation (&lt;2%), anorexia (&lt;2%), constipation (&lt;2%), diarrhea (children: 2% to 3%), dysgeusia (&lt;2%), dyspepsia (&lt;2%), flatulence (&lt;2%), gastritis (&lt;2%), hiccups (&lt;2%), increased appetite (&lt;2%), loose stools (&lt;2%), nausea (&lt;2%), stomatitis (children: 2% to 3%), vomiting (&lt;2%), xerostomia (adolescents and adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Altered micturition (&lt;2%), dysmenorrhea (&lt;2%), impotence (&lt;2%), mastalgia (&lt;2%), urinary incontinence (&lt;2%), urinary retention (&lt;2%), urine discoloration (&lt;2%), vaginitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (children: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (&lt;2%), amnesia (&lt;2%), anxiety (&lt;2%), confusion (&lt;2%), depression (&lt;2%), dizziness (&lt;2%), drowsiness (adolescents and adults: 8%), fatigue (2% to 4%), hypertonia (&lt;2%), hypoesthesia (&lt;2%), insomnia (&lt;2%), irritability (&lt;2%), lack of concentration (&lt;2%), malaise (children: 2%), migraine (&lt;2%), nervousness (children: 4%), nightmares (&lt;2%), paresthesia (&lt;2%), rigors (&lt;2%), vertigo (&lt;2%), voice disorder (children: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (&lt;2%), asthenia (&lt;2%), back pain (&lt;2%), hyperkinetic muscle activity (children: 3%), lower limb cramp (&lt;2%), myalgia (&lt;2%), tremor (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharospasm (&lt;2%), blurred vision (&lt;2%), conjunctivitis (children: 2%), eye pain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (children: 2% to 3%), tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (&lt;2%), bronchospasm (&lt;2%), cough (&lt;2%), dry nose (&lt;2%), dyspnea (&lt;2%), epistaxis (children: 2% to 3%), flu-like symptoms (children: 2% to 3%), hemoptysis (&lt;2%), laryngitis (&lt;2%), pharyngitis (children: 2% to 3%), upper respiratory tract infection (children: 2%), wheezing (children: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breast hypertrophy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function, hepatic necrosis, hepatitis, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p></div>
<div class="block coi drugH1Div" id="F190007"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to loratadine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F189992"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic impairment: Hepatic impairment increases systemic exposure. Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Phenylalanine: Some products may contain phenylalanine.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878528"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p></div>
<div class="block foc drugH1Div" id="F190002"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin: 10 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">GoodSense Allergy Relief: 10 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Loratadine: 5 mg/5 mL (120 mL) [fruit flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free; contains propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin Allergy Childrens: 5 mg/5 mL (240 mL) [alcohol free, dye free, sugar free; contains edetate (edta) disodium, propylene glycol, sodium benzoate, sorbitol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free; contains propylene glycol, sodium benzoate, sodium metabisulfite; peach flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains polyethylene glycol (macrogol), propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains edetate (edta) disodium, propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg/5 mL (120 mL, 240 mL) [alcohol free, dye free, sugar free; contains edetate (edta) disodium dihydrate, propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg/5 mL (10 mL [DSC]) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg/5 mL (120 mL) [sugar free; contains polyethylene glycol (macrogol), propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief: 10 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief (Loratadine): 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief (Loratadine): 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Allergy Relief Loratadine: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT All Day Allergy Relief: 10 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loradamed: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin: 5 mg [contains aspartame, fd&amp;c blue #2 (indigo carm) aluminum lake; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin Childrens: 5 mg [contains aspartame, carmine; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Allergy Relief Childrens: 5 mg [contains aspartame, fd&amp;c blue #2 (indigo carm) aluminum lake; grape flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg [contains aspartame; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Loratadine Childrens: 5 mg [dye free; contains aspartame; bubble-gum flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alavert: 10 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alavert: 10 mg [DSC] [contains aspartame; citrus flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Claritin Reditabs: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triaminic Allerchews: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F189988"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F190009"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Claritin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Loratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Claritin Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Claritin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.24</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Claritin Allergy Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Loratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.05 - $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Claritin Reditabs Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Loratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.93 - $1.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Triaminic Allerchews Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Claritin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Loratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.04 - $0.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F803166"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be administered without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Dispersible tablet: Place in mouth and allow to dissolve. Swallow with or without water.</p></div>
<div class="block admp drugH1Div" id="F52613186"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Rapidly disintegrating tablet: Place rapidly disintegrating tablet on the tongue; tablet disintegration occurs rapidly; may administer with or without water.</p></div>
<div class="block use drugH1Div" id="F190004"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis or conjunctivitis:</b> Relief of nasal and non-nasal symptoms of seasonal allergies.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>OTC labeling: </b>Patient-guided therapy for symptoms of hay fever or other upper respiratory allergies.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous:</b> Treatment of itching due to hives (urticaria).</p></div>
<div class="block mst drugH1Div" id="F6699703"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Claritin may be confused with Clarispray, Claritin Eye (ketotifen), clarithromycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F190063"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F189997"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible. If concomitant use cannot be avoided, monitor QT interval and for signs of dyshythmias (eg, syncope).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Loratadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F190020"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases bioavailability and delays peak. Management: Administer without regard to meals.</p></div>
<div class="block pri drugH1Div" id="F12881433"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Loratadine may be used when a second generation antihistamine is needed. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).</p></div>
<div class="block brc drugH1Div" id="F12881440"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Loratadine and its active metabolite, desloratadine, are present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">The relative infant dose (RID) of loratadine plus desloratadine has been calculated to be 1.1% when compared to a maternal dose of 40 mg/day of loratadine (Hilbert 1988).</p>
<p style="text-indent:0em;margin-top:2em;">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:0em;margin-top:2em;">The RID was calculated by the authors of a study following maternal administration of a single oral dose of loratadine 40 mg to six breastfeeding women between 1 and 12 months' postpartum. The estimated daily infant dose of loratadine equivalents via breast milk was calculated to be 29.1 mcg/day in a theoretical 4 kg infant. The half-life of loratadine in breast milk was reported to be 10.7 hours in one woman (Hilbert 1988).</p>
<p style="text-indent:0em;margin-top:2em;">Drowsiness and irritability have been reported in breastfed infants exposed to antihistamines (Ito 1993). In general, second generation antihistamines (eg, loratadine) are less sedating as compared to their first generation counterparts. If a breastfed infant is exposed to a second generation antihistamine via breast milk, they should be monitored for irritability, jitteriness, or drowsiness (Butler 2014).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment with an antihistamine is needed for the treatment of rhinitis and urticaria in breastfeeding women, a second generation antihistamine, such as loratadine, is preferred (BSACI [Powell 2015]; BSACI [Scadding 2017]; Butler 2014; Zuberbier 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of lactation (Messinis 1985).</p></div>
<div class="block dic drugH1Div" id="F190011"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken without regard to meals. Some products may contain phenylalanine and/or sodium.</p></div>
<div class="block pha drugH1Div" id="F189991"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Long-acting tricyclic antihistamine with selective peripheral histamine H<sub>1</sub>-receptor antagonistic properties</p></div>
<div class="block phk drugH1Div" id="F190006"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetic profile of children 2 to 12 years is similar to that of adults (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1-3 hours (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 8-12 hours (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: &gt;24 hours (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid; food increases total bioavailability (AUC) by 40% to 48% (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 119 L/kg (Haria 1994); binds preferentially to peripheral nervous system H<sub>1</sub> receptors; no appreciable entry into CNS (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97% to 99% (loratadine), 73% to 76% (metabolite) (Haria 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP2D6 and 3A4 to active metabolite (descarboethoxyloratadine) (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 8.4 hours (range: 3 to 20 hours) (loratadine), 28 hours (range: 8.8 to 92 hours) (metabolite) (Claritin prescribing information 2000); hepatic impairment: 24 hours (loratadine), 37 hours (metabolite) (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Loratadine: 1.3 hours (loratadine), 2.3 hours (metabolite) (Claritin prescribing information 2000)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (40%) and feces (40%) as metabolites</p></div>
<div class="block phksp drugH1Div" id="F51153978"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: With CrCl &lt;30 mL/minute, AUC and C<sub>max</sub> are increased approximately 73% for loratadine and 120% for its metabolite.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC and C<sub>max</sub> doubled for loratadine</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC and C<sub>max</sub> are increased approximately 50%, and t<sub>½</sub> ranged from 6.7 to 37 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F190012"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Clara | Claritin kids | Claritine | Emilora | Klarfast | Lohist | Loracare | Loradad | Loraday | Lorahist | Loralife | Lorano | Loratin | Lorine | Lorine fm | Mosedin | Neoday | Restamine | Roletra | Tectaler | Tidilor</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aerotina | Alergiano | Alergitrat L | Alermuc | Alerpriv | Antialergico | Aparzo | Bedix | Benadryl 24 Flash | Biloina | Clarityne | Devedryl | Dexitis | Hisplex | Lertamine | Liberol flash | Lisaler | Loisan | Loratadina | Loratadina Fabra | Loratadina Gezzi | Loratadina ilab | Loratadina indeco | Loratadina northia | Loratadina tauro | Loratadina vannier | Loratex | Loratine | Mudantil L | Nastizol antialergico | Negalerg | Nularef | Omega 100 l | Predual l | Primer nivel | Pulmosan Aller | Refenax Antialergico | Ronedina | Sinaler | Tabcin alergia | Vagran | Vixidone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Allernon | Clarityn | Lictyn | Lorano | Loratadin | Loratadin arcana | Loratadin ratiopharm | Loratadin stada artzneimittel | Loratadin-alternovaatzneimittel | Toppoll</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alledine | Allerdyne | Allereze | Amcal loratadine | Apohealth loratadine | Apohealth loratadine hayfever &amp; allergy relief | Blooms the chemist loratadine | Cetedyne | Chemmart loratadine | Chemplus loratadine | Children's Claratyne | Claratyne | Cm Loratadine | Demazin allergy + hayfever relief | Guardian loratadine | Lorano | Lorapaed | Lorastyne | Medihealth loratadine | Pc Loratadine | Pharmacist Formula Loratadine | Pharmacy care loratadine | Pharmacy health loratadine | Priceline loratadine | Terry white chemists loratadine | Trust Loratadine | Tw Loratadine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alaron | Aleze | Analor | Cladin | Claritine | Din | Eladin | Elo | Encilor | Eradex | Lodin | Lora | Loradin | Lorastine | Lorat | Loratec | Loratin | Loratin-ft | Loren | Lorfast | Lorin | Noseral | Oradin | Orin | Pretin | Relor | Silora | Tide | Tirlor</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Loratadine bexal | Loratadine eg | Loratadine merck-generics | Loratadine Sandoz | Loratadine teva generics belgium | Sanelor</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Clarityne | Clartec | Loratol | Lorhist | Lorinol | Pretin | Tirlor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Loratadin | Loredin | Roletra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alergaliv | Atinac | Clarilerg | Claritin | Cloratadd | Histadin | Histalor | Histamix | Lergitec | Loradine | Loralerg | Loranil | Lorasc | Lorasliv | Loratadina | Loratamed | Loremix | Loritil | Neo Loratadin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Lora Mepha Allergi | Lorado | Lorado Pollen | Loratadin Actavis | Loratadin Helvepharm | Loratadin Sandoz | Loratin Mepha</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Akaryd | Allergine | Loractiv | Loractyne | Loratadine generis | Loratadine hakim | Lorhist | Lorinol | Lorix</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alergan | Alledryl | Artamina | Clarityne | Frenaler | Histaplus | Histidanyl | Larmax | Lontadex | Loptame | Loratadina | Loretina | Primorix | Zinlergia</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao hui feng | Ao mi xin | BAI WEI LE | Bai wei tan | Bang nuo | Bi sai ning | Bi yan tong | Chang ke | Clarityne | Da sheng rui li | Fei ge man | Fu lai xi | Jing wei | Ke mi | Kui yin | Lei ning | Min li ke | Nuo ding | She tai | Shi nuo min | Shu rui | Shun ta xin | Tai ming ke | Tian qing zheng shu | Tian tu | Tianqing zheng shu | Xin da yue | Xue fei | Xue su | Yi bang | Yi fei | Yi li xin | Yi shu chang | Zhi min</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alatrin | Alerclar | Atadin | Cladine | Clarityne | Clarityne rapitabs | Efectine | Eutarpan | Exul | Hislort | Histabloq | Histaloran | Histapen | Loracert | Lorad | Loramine | Loratadina | Loratadina mk | Lordinex | Loreken | Lorex | Loristat | Lorydin | Noxin | Ponderal | Relergic | Rinil | Tadine | Valket</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Flonidan | Loranol | Loratadin | Roletra</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clarityne | Gib Loratadin | Lisino | Lobeta gegen allergien | Lora | Lora ADGC | Lora lich | Loraderm | Loragamma | Lorano | Lorano akut | Loratadin | Loratadin acis | Loratadin akut | Loratadin axi | Loratadin axicur | Loratadin beta | Loratadin CT | Loratadin ksk | Loratadin ratiopharm bei Allergien | Loratadin Sandoz | Loratadin Stada | Loratadura | Loratagamma | Loravis</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Loratadin alpharma | Mildin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aler ka | Alerin | Antial | Clarityne | Desolin | Efectine | Floginax | Frenaler | Inalor | Loragen | Loraler | Loratadina | Loratadina Calox | Loratadina lam | Loratadina quidom | Loratadina sued | Loratafran | Medilorat | Proactin | Sensibit | Sinhistan | Tabcin alergia | Tirlor | Zoman</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alerfast | Alerflash | Alergin | Alergit | Alerpriv | Alervic | Aloratt | Clarityne | Efectine | Frenaler | Histaloran | Histaplus | Hysticlar | Larotin | Loratadina | Loratadina la sante | Loratadina mk | Loratadina-R | Loratin | Lorexin | Proactin | Tricel | Vilamax | Zoman</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Clarityn | Loradon | Loratadine actavis | Loratadine Sandoz | Loratin | Loratin express | Rinolan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Histlor | Laratan | Lorano | Loraswab | Loratan | Loratin | Lorine | Mosedin | Sedclarit | Uniloratadine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Civeran | Clarityne | Loratadina bayvit | Loratadina bexal | Loratadina cinfa | Loratadina combix | Loratadina Cuve | Loratadina davur | Loratadina kern | Loratadina Korhispana | Loratadina lasa | Loratadina normon | Loratadina Pharmagenus | Loratadina qualigen | Loratadina ranbaxy | Loratadina Ratiopharm | Loratadina rimafar | Loratadina Tamarang | Loratadina tarbis | Loratadina UR | Velodan</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Loradine | Lorastamin | Lorazim | Lorman | Mosedin | Remidine | Ticevis | Tidilor</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clarityn | Histadin | Loradatin sandoz | Loratadin Actavis | Loratadin alpharma | Loratadin durascan | Loratadin generics | Loratadin hexal | Loratadin ratiopharm | Loratadin Sandoz | Loratadin Stada | Loraxin | Tuulix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clarityne | Doliallergie loratadine | Humex allergie loratadine | Loratadine actavis | Loratadine Almus | Loratadine Arrow | Loratadine Biogaran | Loratadine Cristers | Loratadine eg | Loratadine mylan | Loratadine Nepenthes | Loratadine Qualimed | Loratadine Ranbaxy | Loratadine Ratiopharm | Loratadine Sandoz | Loratadine Winthrop | Loratadine Zydus | Zaprilis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Asda hayfever &amp; allergy | Boots hayfever relief all day | Clarityn | Clarityn allergy | Clarityn Rapide Allergy | Em pharma one a day allergy | Hayfever &amp; allergy | Hayrite | Lorapaed | Loratadine cox | Loratadine kent | Loratadine Sandoz | Loratadine teva | Non drowsy allergy relief | Non drowsy hayfever &amp; allergy relief | Roletra</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Allergofact | Biliranin | Bollinol | Clarityne | Difmedol | Helporigin | Horestyl | Latoren | Lora | Loratab | Novacloxab | Ralinet | Utel | Zelmar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Allergone | Allertyn | Allor | Ambrace | Anhissen | Apo loratadine | Carin | Clarin | Clarinet | Clarityne | Cp Loradine | Euritin | Ezede | Folerin | Genadine | Kalidin | Loranox | Loratadin | Loratadina | Loraton | Lorita | Lortin | Lorytec | Lotadine | Lotin | Natsin Day | Nt alergi | Ratadine | Rinityn | Sunadine | Synratadine | Tirlor | Uni Claritin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Belodin | Belodin a | Claritine | Claritine Alergija | Contral | Flonidan | Rinolan | Rinolan Alerg</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Claritine akut | Erolin | Flonidan | Loratadin hexal | Loratadin ratiopharm | Roletra</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alerhis | Alernitis | Allohex | Alloris | Anhissen | Anlos | Clarihis | Claritin | Clarixin | Clatatin | Cronitin | Dayhist | Dinazen | Folerin | Gradine | Hislorex | Histaritin | Imunex | Inalergi | Inclarin | Klinset | Lergia | Lesidas | Logista | Loran | Lorapharm | Loratadin | Lorihis | Nosedin | Nufalora | Omellegar | Prohistin | Pylor | Rahistin | Rihest | Safetin | Sohotin | Soneryl | Tinnic | Winatin | Xepalodin | Zeos</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clareeze Allergy | Clarityn | Histaclar | Lorat</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lorastine | Loratadine teva | Loratrim</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alaspan | Alastin | Alerta | Algyfree | Alorti | Avil advance | Awayke | Claridin | Cozy | Eldin md | Lohist | Lomax | Lor | Loract | Loratin | Lorfast | Lorid | Loridin | Lorin | Lorinol | Lormeg | Loronet | Lorsyn | Lortab dt | Lortadin | Lotic | Olang | Rapidin | Roletra | StopAllerG | Talor | Tarol | Tirlor</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Aswatadin | Laritin | Loradin | Loradix | Lorasaf | Lorasam | Loratadin awa | Lorax</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Loritin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alorin | Clarityn | Fristamin | Loratadina EG | Loratadina ranbaxy | Loratadina Sandoz</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Clara | Claritine | Histal | Klarihist | Lohist | Loratan | Lorax | Loreen | Lorine | Lormine | Ramitin | Rayon | Restamine | Tidilor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Claritin | Claritin ex | Claritin shionogi | Loratadine Amel | Loratadine ffp</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cetin | Claritine | Folerin | Histachlor | Loractiv | Loradine | Loraglob | Loras | Lorata | Loraten | Loratin | Loratin fast | Loratyn | Loreze | Lorfast | Lorhistina | Lorix | Lorvic | Lorytec | Lotin | Neoday | Pretin | Soloratidin | Tidilor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aletin | Alleoff l | Allerno | Alleroff l | Allertadine | Alletin | Alletine | Allostop | Alostop | Claritin | Clarityne | Clarityne radi | Cleardin | Daewoo loratadine | Ejyasmin | Ethytadin | Ezasmin | Floradin | Histadin | Histafa | Histapa | J-tadine | Jeil algyssak lora | Jeratadine | Lodain | Loradine | Loragen | Loran | Loranil | Loratadine guju | Loratadine sa | Loratain | Loratin | Loratyn | Lorazin | Loridin | Nelson loratadine | Newrodine | Norapin | Noratin | Notamin | Rastadin | Sinotadine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo loratadine | Clara | Claritine | Emilora | Klarihist | Lohist | Loracare | Loraday | Lorano | Loratan | Loratin | Loraxine | Lorine | Lorine fm | Lorytec | Mosedin | Neoday | Restamine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo loratadine | Clara | Claritine | Histal | Loradad | Loratan | Loratin | Lorine | Oradin | Oradine | Ramitin | Restamine | Xanidin | Zifar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Flonidan | Lomilan | Loradon | Loratadin 10-sl | Loratadin bijon | Loratadine actavis | Loratadine Alpharma | Loratadine bijon | Loratadine teva | Loratin | Loridin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Lorano | Rupton | Sanelor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Lomilan | Loracip | Loradin | Loratadin | Loratin | Loratin express | Loridin | Rinolan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Allergine | Clarityne | Clartec | Histanorm | Loractine | Zifar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Albatrina | Alenous | Alsaltor | Aludix | Alviumito | Antilergal | Biolorat | Cilora | Clarigen | Clarityne | Clarityne zydis | Curyken | Dimegan | Ditana | Doralan | Dotagil | Efectine | Grimeral | Histina | Histox | Hl Ysta | Inigrin | Israimel | Laritol | Lertamine | Licortin | Lictyn | Liduqa | Liferamin | Loramsa | Loratadina | Loratadina farmaco | Loratadina gi kend | Loratadina gi mave | Loratadina gi serr | Loratadina Iqfa | Loratadina Landsteiner | Loratadina Loeffler | Loratadina Teva | Lotan | Lotinex | Lovarin | Lowadina | Neoalexil | Nidatar | Quimtadine | Rinard | Roletra | Sensibit | Serralsina | Simablok | Sitinir | Tadinar | Tadinose | Terentia | Urtisin | Vincidal | Zeryne</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo loratadine | Avotyne | Axcel loratadine | Carin | Clarityne | Dyna Loratadine | Ezede | Halon | Loradine | Loradyne | Lorastyne | Loratadin Stada | Loraten | Loratyn-10 | Lorazin | Loridin | Lorsedin | Rhinitin | Ridamin | Roletra | Rotifar | Sunadine | Zoratadine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Afrab loratadine | Claritine | Esley loratadine | Everdestiny loratadine | Greenhope loratadine | Hanritin | Julordin | Kinratyn | Lalora | Lantine | Lorergy | Nectadine | Pinnacle loratadine | Pretadin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Allerfre | Claritine | Clarityne | Kruidvat hooikoortstabletten loratadine | Loratadine Hexal | Loratadine hooikoortstabletten Apotex | Loratadine Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Clarityn | Clarityn S | Clarityne | Loratadin | Loratadin BMM Pharma | Loratadin copyfarm | Loratadin gea | Loratadin hexal | Loratadin Orifarm | Loratadin Sandoz | Versal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo loratadine | Children's Claratyne | Claratyne | Lora-tabs | Loraclear | Loraclear Hayfever Relief | Lorafix | Lorfast | Pharmacy health loratadine hayfever &amp; allergy relief</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Alerfast | Alergiatadina | Alertadin | Alertil | Alledryl | Allergy tadina | Avallert | Clarityne sp | Cronopen | Dimens | Eclaran | Efecutin | Histafren | Loralab-d | Loralerghyna | Lorastamin | Lorat | Loratadina | Loristal | Loristat | Loritex | Nasaler | Oratadina allergy | Proactin | Rinalor | Roletra | Tirlor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actidin | Allergix | Allerta | Allisin | Allor | Antal | Biobril | Carin | Clarihist | Claritin | Histadine | Immunix | Laradin | Lergicyl | Loaller | Loradex | Loradine | Lorafix | Lorahist | Lorange | Lorano | Lorarex | Lorat | Lordam | Lordamin | Lorexa | Lorfast | Lorid | Onemin | Prevahist | Rinityn | Rm loratadine | Sylergy | Toral | Zylohist</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Al care | Alavert | Alerde | Alerfree | Alertine | Alerway | Allerget | Allerwood | Allorat | Alor | Alten | Andin | Antial | Antimin | Axalor | Baxadin | Cara gix | Celestin | Claritine | Clarix | Clazine | Clintal | Clintol | Conrat | Dinclor | Dinsave | Ezitine | Floret | Fozil | Frend | Gollergic | Haylief | Hico-od | Hispar | Hisplex | Histadine | Histamac | Histanil | Histar | Historat | Jade | Korat | Laraib | Leksus | Lohist | Loin | Lolergy | Lor | Loradine | Loragix | Loramax | Loramed | Loranees | Loratad | Loratamed | Loratascot | Lorate | Lorated | Loratine | Loratlax | Loratop | Lorazid | Lorcet | Lordin | Lorefect | Lorel | Lorex | Lorid | Lorin-nsa | Lornas | Lortab | Lortamine | Lortec | Lortin | Lortin D | Losad | Lotad | Lotin | Lumfort | Mastal | Maxotel | Megalor | Momtek | Mydin | Nonsed | Notres | P-Lor | P-sur | Relent | Resotin | Rhilor | Rhinamin | Rudin | Sedinor | Selectin | Selordine | Senergy od | Sinease | Softin | Synadin | Talergin | Tavelor | Teldrin | Telkot | Texcol allergy | Tirlor | Urti-Care | Velair | Verat | Victrin | Widine | Xylor | Zestress | Zorat | Zordin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alerfan | Aleric | Claritine | Claritine allergy | Claritine spe | Flonidan | Flonidan control | Lorahexal | Loram | Loratadine 1A Pharma | Loratadyna | Loratadyna Pylox | Loratan | Loratine | Nalergine | Rotadin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Alavert | Allergy Relief | Children's Claritin | Children's loratadine | Claritin | Claritin Hives Relief | Claritin Reditabs | Clear-Atadine | Tavist nd</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alertrin | Claritine | Loratadina | Loratadina mylan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alercrom | Biloina | Clarityne | Histafren | Lontadex | Loraler | Loratadina bilac | Loratadina cellofarm | Loratadina dallas | Loratadina kirei | Loratadina la sante | Paralergim | Sinaler</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Clara (Jamjoom) | Claritine | Emilora | Klarihist | Lohist | Loradad | Loraday | Loradox | Loramax | Lorano | Loratin | Loreen | Lorine | Lorine FM | Neoday | Oradine | Ramitin | Rayon | Restamine | Tidilor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Flonidan | Latoren | Lorastamin | Loratadina biofarm | Loratadina sintofarm | Loratadina slavia | Loratan | Symphoral</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alerpriv | Clargotil | Clarifarm | Clarifer | Clarisens | Claritine | Clarnedin | Clarotadin | Clarotadine | Erolin | Klallergin | Klallergine | Klarfast | Klaridol | Klarifer | Klarisens | Lomilan | Loradin | Lorahexal | Loratadine eco | Loratadine hemofarm | Loratadine stada | Loratadine teva | Loratadine vertex | Loratadinum kmp | Loratavel | Loratin | Loridin | Vero loratadine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo loratadine | Clara | Claritine | Glora | Lohist | Lojour | Loraday | Lorahist | Loramax | Lorano | Loratin | Lorine | Neoday | Ramitin | Restamine | Tidilor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clarityn | Clarityn S | Loratadin 2care4 | Loratadin abece | Loratadin Actavis | Loratadin Apofri | Loratadin BMM Pharma | Loratadin copyfarm | Loratadin hexal | Loratadin Mylan | Loratadin Orifarm | Loratadin ratiopharm | Loratadin Sandoz | Loratadin Stada | Versal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Allertyn | Clarityne | Ezede | Halodin | Histalor | Loradine | Loratyn | Lorfast | Loridin | Ridamin | Rinityn | Roletra</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Claritine S | Flonidan | Flonidan S | Rinolan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Claritine | Erolin | Flonidan | Loranol | Loratadin | Restamine | Rinolan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alertyne | Aller-tab tab | Allerdine | Allernix | Allersil | Allex | Aridine | Atloftin | Botidine | Cantadine | Caradine | Carinose | Cetyne | Clalergy | Clalodine | Clarid | Claridine | Clarine | Claritex | Claritino | Clarityne | Clatidyne | Clatidyne O | Cloresian | Daytadine | Faradin | Fatyne | Gaprodine | Halodin | Hisracon | Histadine | Kalidin | Klaryne | Lindine | Linityne | Logadine | Loracine | Loradine | Loragis | Loramed | Loramex | Loranox | Loratyne | Lordamin | Lordin | Loridin | Lorinase | Lorita | Lorityne | Lorsedin | Lortadine | Lortec | Lotidyne | Moradine | Piptaryne | Ridamin | Rityne | Roletra | Sanotyne | Soratadine | Startyne | Talidene | Taridine | Tiradine | Tirlor | Villergy</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Clarityne | Histadine | Loradine | Oramine | Restamine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alarin | Allertidin | Antor | Claritine | Hismen | Histadin | Klodin | Loradif | Lorateva | Loritine | Ritin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Besumin | Clarityne | Clatine | Finska | Fucole Minlife | Genadine | Lomidine | Lora | Loradin | Lorastyne | Loratyn | Lorchimin | Losta | Lotarin | Minlife | Mintapp | Rodamine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Agistam | Aleric | Claridol | Claritine | Erolin | Flonidan | Klarifer | Lorano | Loratadin | Loratadine sl | Lorfast | Loridin rapid | Lorizan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Antimin | Axcel loratadine | Claritine | Klarol | Loras | Lorased | Lorhistina | Loridin | Lorytec | Lumfort | Mosedin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alerfast | Alergipan | Alerton | Biloina | Clarityne | Efecutin | Flodin NF | Frenaler | Frenistal | Hisplex | Hisradin | Loratadina | Loratadina Pellier | Loratil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alerdina | Alertidine | Clarityne | Loradex | Loradin | Loratadina | Loraval | Lorex | Loriden | Lotal | Polaramine reformulado | Proactin | Roletra | Sitadin | Tirlor</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agilodin | Axota | Bolorate | Clanoz | Eftilora | Ganusa | Hamistyl | Lohatidine | Lorabay | Loradil | Lorastad | Lortalesvi | Roustadin | Usalota | Usarad | Ustadin | Vaco loratadine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Allergex non drowsy | Ap Loratadine | Apex Loratadine | Cipla Loratadine | Clarinese | Clarityne | Demazin anti-allergy | Laura | Lorahist | Lorano | Loratadine biotech | Loratyne | Lormeg | Pollentyme | Rhinigine | Rolab-loratadine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Allerban | Allerdin | Claritine | Lorano | Loratan | Loridin | Lormeg | Pollentyme | Pollentyme s</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Axcel loratidine | Lorano | Loratin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Alavert (loratadine) [prescribing information]. New York, NY: Pfizer Consumer Healthcare; no date.</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007:95-168.</div>
</li>
<li>
<div class="reference">
                  Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Children's Claritin Allergy (loratadine) [prescribing information]. Whippany, NJ: Bayer Healthcare LLC; 2017.</div>
</li>
<li>
<div class="reference">
                  Claritin Chewables (loratadine) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Claritin.3">
<a name="Claritin.3"></a>Claritin Children's Chewables (loratadine) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received January 2023.</div>
</li>
<li>
<div class="reference">
                  Claritin Syrup (loratadine) [package insert]. Kenilworth, NJ: Schering Corporation; July 2000.</div>
</li>
<li>
<div class="reference">
                  Claritin tablets (loratadine) [prescribing information]. <b></b> Whippany, NJ: Bayer HealthCare LLC; 2020.</div>
</li>
<li>
<div class="reference">
                  Claritin tablets, syrup, rapidly-disintegrating tablets (loratadine) [product information]. Kenilworth, NJ: Schering Corporation; September 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7528133">
<a name="7528133"></a>Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. <i>Drugs</i>. 1994; 48(4):617-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/7528133/pubmed" id="7528133" target="_blank">7528133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2966185">
<a name="2966185"></a>Hilbert J, Radwanski E, Affrime MB, et al. Excretion of loratadine in human breast milk. <i>J Clin Pharmacol.</i> 1988;28(3):234-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/2966185/pubmed" id="2966185" target="_blank">2966185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference">
                  Loradamed [package insert]. Fort Myers, FL: Medique Products; May 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2140371">
<a name="2140371"></a>Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. <i>J Clin Pharmacol</i>. 1990;30(4):364-371. doi:10.1002/j.1552-4604.1990.tb03607.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/2140371/pubmed" id="2140371" target="_blank">2140371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Pozzo-Magaña BR. Chronic urticaria in children: a review. <i>EMJ Dermatol</i>. 2017;5(1):74-82.</div>
</li>
<li>
<div class="reference">
                  Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909915">
<a name="7909915"></a>Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. <i>N Engl J Med</i>. 1994;330(23):1663-1670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/7909915/pubmed" id="7909915" target="_blank">7909915</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Published July 18, 2017. Accessed November 2, 2018.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Updated February 8, 2018. Accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/loratadine-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9572 Version 768.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
